BeOne Medicines Ltd. (ONC) Revenue History
Annual and quarterly revenue from 2013 to present
ONC Revenue Over Time (2013–2025)
ONC Revenue Growth History
8 of 12 years with positive growth- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- +16.9%
- FY2015 revenue growth
- -32.4%
- FY2016 revenue growth
- -87.9%
- FY2017 revenue growth
- +22179.2%
- FY2018 revenue growth
- -16.8%
- FY2019 revenue growth
- +116.0%
- FY2020 revenue growth
- -27.9%
- FY2021 revenue growth
- +280.8%
- FY2022 revenue growth
- +20.4%
- FY2023 revenue growth
- +73.7%
- FY2024 revenue growth
- +55.0%
- FY2025 revenue growth
- +40.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $1.51B | +35.5% |
| Q4 2025 | $1.50B | +32.8% |
| Q3 2025 | $1.41B | +41.0% |
| Q2 2025 | $1.32B | +41.6% |
| Q1 2025 | $1.12B | +48.6% |
| Q4 2024 | $1.13B | +77.8% |
| Q3 2024 | $1.00B | +28.2% |
| Q2 2024 | $929.2M | +56.1% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
ONC's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ONC Revenue Analysis (2013–2025)
Current Revenue & Growth
As of June 28, 2026, BeOne Medicines Ltd. (ONC) generated trailing twelve-month (TTM) revenue of $5.74 billion, reflecting explosive growth of +35.5% year-over-year. The most recent quarter (Q1 2026) recorded $1.51 billion in revenue, up 1.0% sequentially.
Historical Growth Trajectory
ONC's 5-year compound annual growth rate (CAGR) stands at +76.8%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +55.7% is below the 5-year average, signalling a growth deceleration in recent years. BeOne Medicines Ltd.'s highest annual revenue of $5.34 billion was recorded in 2025, an all-time high.
Revenue by Segment
ONC's revenue is primarily driven by Product (99%), and Collaboration (1%). With over half of revenue concentrated in Product, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ZYME (-13.0% YoY), RCUS (+67.4% YoY), and TGTX (+81.3% YoY) — ONC has outperformed the peer group in revenue growth. Compare ONC vs ZYME →
ONC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ONCCurrent | $5.7B | +35.5% | +76.8% | 8.4% | |
 ZYME | $106M | -13.0% | +22.2% | -87.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 MGNX | $150M | +3.1% | +8.9% | -48.7% |
ONC Historical Revenue Data (2013–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.34B | +40.2% | $4.67B | 87.5% | $447.1M | 8.4% |
| 2024 | $3.81B | +55.0% | $3.22B | 84.4% | $-568,199,000 | -14.9% |
| 2023 | $2.46B | +73.7% | $2.08B | 84.5% | $-1,207,736,000 | -49.1% |
| 2022 | $1.42B | +20.4% | $1.13B | 79.8% | $-1,789,665,000 | -126.4% |
| 2021 | $1.18B | +280.8% | $1.01B | 86.0% | $-1,438,735,000 | -122.3% |
| 2020 | $308.9M | -27.9% | $238.2M | 77.1% | $-1,657,682,000 | -536.7% |
| 2019 | $428.2M | +116.0% | $357.0M | 83.4% | $-959,891,000 | -224.2% |
| 2018 | $198.2M | -16.8% | $-509,490,000 | -257.0% | $-705,769,000 | -356.1% |
| 2017 | $238.4M | +22179.2% | $-35,605,000 | -14.9% | $-98,457,000 | -41.3% |
| 2016 | $1.1M | -87.9% | $-96,963,000 | -9062.0% | $-117,060,000 | -10940.2% |
| 2015 | $8.8M | -32.4% | $-49,434,000 | -560.7% | $-56,745,000 | -643.7% |
| 2014 | $13.0M | +16.9% | $-8,827,000 | -67.7% | $-15,757,000 | -120.9% |
| 2013 | $11.1M | - | $-2,315,000 | -20.8% | $-5,458,000 | -49.0% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ONC — Frequently Asked Questions
Quick answers to the most common questions about buying ONC stock.
Is ONC's revenue growth accelerating or slowing?
ONC revenue growth is accelerating. TTM revenue reached $5.7B, up +35.5% year-over-year — ahead of the 5-year CAGR of +76.8%. This indicates the business is expanding faster than its historical baseline.
What is ONC's revenue history from 2013 to 2026?
BeOne Medicines Ltd. (ONC) revenue history spans 2013 to 2026. TTM revenue as of 2026 is $5.7B, growing at +35.5% YoY. The 5-year CAGR is +76.8%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ONC's long-term revenue growth rate (CAGR)?
BeOne Medicines Ltd.'s 5-year revenue CAGR of +76.8% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +35.5% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ONC.
Why does ONC's quarterly revenue fluctuate?
ONC quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. BeOne Medicines Ltd.'s revenue data from 2013 to 2026 shows full historical quarterly detail on this page.
How is ONC's revenue distributed by segment?
ONC reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ONC's revenue compare to industry peers?
BeOne Medicines Ltd. (ONC) with TTM revenue of $5.7B and +35.5% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.